Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-MVA Triplex Vaccination in Stem Cell Donors to Prevent CMV in Recipients
NCT06059391Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in cytomegalovirus infection (CMV) comparing Arm I (Triplex vaccination) with Arm II (Placebo) (2 arms). Primary endpoints: Time from transplantation to cytomegalovirus (CMV) disease or pre-emptive treatment following CMV reactivation, Occurrence of non-relapse mortality and 3 more. Started Jul 2024; status: recruiting.
02
Drugs
Triplex
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06059391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059391.